ATE279438T1 - Entzündungshemmende verbindungen und ihre verwendung - Google Patents

Entzündungshemmende verbindungen und ihre verwendung

Info

Publication number
ATE279438T1
ATE279438T1 AT01935035T AT01935035T ATE279438T1 AT E279438 T1 ATE279438 T1 AT E279438T1 AT 01935035 T AT01935035 T AT 01935035T AT 01935035 T AT01935035 T AT 01935035T AT E279438 T1 ATE279438 T1 AT E279438T1
Authority
AT
Austria
Prior art keywords
inflammatory compounds
inflammatory
compounds
Prior art date
Application number
AT01935035T
Other languages
English (en)
Inventor
Michael J May
Sankar Ghosh
Mark A Findeis
Kathryn Phillips
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE279438T1 publication Critical patent/ATE279438T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
AT01935035T 2000-05-02 2001-05-02 Entzündungshemmende verbindungen und ihre verwendung ATE279438T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20126100P 2000-05-02 2000-05-02
US09/643,260 US6864355B1 (en) 2000-05-02 2000-08-22 Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
PCT/US2001/014346 WO2001083554A2 (en) 2000-05-02 2001-05-02 Anti-inflammatory compounds and uses thereof

Publications (1)

Publication Number Publication Date
ATE279438T1 true ATE279438T1 (de) 2004-10-15

Family

ID=26896561

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01931171T ATE339440T1 (de) 2000-05-02 2001-05-02 Entzündungshemmende verbindungen und ihre verwendung
AT01935035T ATE279438T1 (de) 2000-05-02 2001-05-02 Entzündungshemmende verbindungen und ihre verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01931171T ATE339440T1 (de) 2000-05-02 2001-05-02 Entzündungshemmende verbindungen und ihre verwendung

Country Status (11)

Country Link
US (6) US6864355B1 (de)
EP (4) EP1282643B1 (de)
JP (4) JP2003531636A (de)
AR (1) AR031696A1 (de)
AT (2) ATE339440T1 (de)
AU (3) AU2001257631B2 (de)
CA (2) CA2414290A1 (de)
DE (2) DE60106423T2 (de)
ES (1) ES2231494T3 (de)
TW (1) TWI316062B (de)
WO (2) WO2001083554A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (de) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7049395B2 (en) * 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
AU2002247191A1 (en) * 2001-02-16 2002-09-04 University Of Southern California A composition and method for reconstituting i$g(k)b kinase in yeast and methods of using same
US20030171253A1 (en) * 2001-04-19 2003-09-11 Averil Ma Methods and compositions relating to modulation of A20
US20030165985A1 (en) * 2001-05-08 2003-09-04 Derry Jonathan M.J. Methods for identifying compounds that antagonize cd40 signaling
US7033991B2 (en) 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
CA2458677A1 (en) * 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
DE60305446T4 (de) * 2002-01-07 2009-07-09 Eisai R&D Management Co., Ltd. Desazapurine und deren verwendung
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
BRPI0414714A (pt) * 2003-09-24 2006-11-21 Pasteur Institut polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (de) 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
CA2646316C (en) 2006-03-15 2016-05-24 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
CN103211821A (zh) 2006-04-22 2013-07-24 霍利斯—伊登医药公司 药物和用途
US7919579B2 (en) * 2006-10-27 2011-04-05 The Board Of Regents Of The University Of Texas System Imaging and therapeutic targeting of prostate and bladder tissues
EP2152726B8 (de) * 2007-05-01 2015-02-18 Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP Analgetische verbindungen
US20090075902A1 (en) * 2007-05-25 2009-03-19 Robbins Paul D Inhibiting the signs of aging by inhibiting nf-kappa b activation
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
FR2927080A1 (fr) * 2008-02-05 2009-08-07 Servier Lab Structure cristalline du domaine cc2-lz de nemo
PT2440231T (pt) 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos
KR101122845B1 (ko) * 2009-07-30 2012-03-21 부산대학교 산학협력단 경구용 염증성 장질환 치료제
EP3210611B1 (de) * 2010-03-12 2019-08-21 The Brigham and Women's Hospital, Inc. Verfahren zur behandlung von gefässentzündungserkrankungen
WO2012154684A2 (en) * 2011-05-06 2012-11-15 University Of Rochester Method of preventing development of psoriatic lesions
JP2015509949A (ja) * 2012-02-23 2015-04-02 エンコード バイオ， インコーポレイテッド Ｎｅｍｏ結合ドメイン融合タンパク質
EP2915881A4 (de) * 2012-11-01 2016-07-13 Univ Kyoto Fibrotisches nichtmenschliches tier und verwendung
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
KR101576904B1 (ko) 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
EP3197474B1 (de) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitoren der nf-kappa-b-aktivität zur behandlung von krankheiten und leiden
EP3515452B1 (de) 2016-09-22 2023-09-13 Mercator Medsystems, Inc. Behandlung einer restenose mit temsirolimus
CA3043464A1 (en) 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
US10913773B2 (en) 2016-11-22 2021-02-09 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
WO2018218182A1 (en) 2017-05-26 2018-11-29 Mercator Medsystems, Inc. Combination therapy for treatment of restenosis
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3746105A4 (de) 2018-01-29 2022-05-18 Ohio State Innovation Foundation Zyklische peptidylinhibitoren der cal-pdz-bindenden domäne
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
CN111760174B (zh) 2018-03-14 2023-08-25 墨卡托医疗系统公司 用于局部药物递送的医疗器械和医疗方法
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
EP4308234A4 (de) * 2021-03-16 2025-01-22 Rush University Medical Center Verfahren zur behandlung neurodegenerativer erkrankungen mit peptid mit intranasalem nf-kappab-etherzielmodifikator (nemo)-bindungsdomäne (nbd)
CN113214356B (zh) * 2021-06-03 2023-02-21 兰州大学 十氟联苯环化修饰的nbd多肽类似物及其制备方法和应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5466585A (en) 1986-04-15 1995-11-14 Ciba-Geigy Corporation Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
US5889150A (en) 1991-01-18 1999-03-30 New York University Medical Center Expression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target protiens
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US5889169A (en) 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
WO1993006123A1 (en) 1991-09-20 1993-04-01 Fred Hutchinson Cancer Research Center Human cyclin e
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US5882894A (en) 1991-11-20 1999-03-16 Trustees Of Dartmouth College Nucleic acids encoding CR8 polypeptides, vector and transformed cell thereof, and expression thereof
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5888981A (en) 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
AU2766195A (en) 1994-06-03 1996-01-05 Brigham And Women's Hospital Identification of polycystic kidney disease gene, diagnostics and treatment
US5667987A (en) 1994-07-12 1997-09-16 Bristol-Myers Squibb Company P53 response genes
US5885580A (en) 1994-07-29 1999-03-23 Ajinomoto Co., Inc. Anti-AIDS secretory recombinant BCG vaccine
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
IL116026A (en) 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5895813A (en) 1995-10-13 1999-04-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Diagnosis and treatment of TKA-1 related disorders
US5891643A (en) 1995-11-14 1999-04-06 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
ZA9610721B (en) 1995-12-21 1998-06-19 Cornell Res Foundation Inc Grapevine leafroll virus proteins and their uses.
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
US5905146A (en) 1996-03-15 1999-05-18 University Of Arkansas DNA binding protein S1-3
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5648238A (en) 1996-06-18 1997-07-15 Incyte Pharmaceuticals, Inc. Human protein kinase C inhibitor homolog
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5908756A (en) 1996-08-30 1999-06-01 Johns Hopkins University Protein inhibitor of neuronal nitric oxide synthase
US5876972A (en) 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
US5874290A (en) 1996-11-08 1999-02-23 Northwest Biotherapeutics, Llc Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US5885803A (en) 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
US5851812A (en) 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US5885779A (en) 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
DE69836227T2 (de) * 1997-12-16 2007-08-23 Genencor International, Inc., Palo Alto Verfahren zur herstellung egiii-ähnlicher enzyme
US6030834A (en) 1997-12-30 2000-02-29 Chiron Corporation Human IKK-beta DNA constructs and cells
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
ES2318906T3 (es) 1998-11-13 2009-05-01 Cyclacel Limited Vectores de transposicion derivados de helice 3 de homeodominio de antennapedia.
US5972655A (en) 1998-11-19 1999-10-26 The Research Foundation Of State University Of New York Y2H61 an IKK binding protein
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof

Also Published As

Publication number Publication date
US7538089B2 (en) 2009-05-26
US7872094B2 (en) 2011-01-18
US20050143302A1 (en) 2005-06-30
DE60123041T2 (de) 2007-04-05
AR031696A1 (es) 2003-10-01
DE60123041D1 (de) 2006-10-26
CA2414290A1 (en) 2001-11-08
WO2001083554A3 (en) 2002-08-01
TWI316062B (en) 2009-10-21
US20110160119A1 (en) 2011-06-30
EP1829888A1 (de) 2007-09-05
AU5763101A (en) 2001-11-12
CA2414296A1 (en) 2001-11-08
US20090286736A1 (en) 2009-11-19
JP2003531636A (ja) 2003-10-28
AU6116401A (en) 2001-11-12
JP2012100663A (ja) 2012-05-31
US8217138B2 (en) 2012-07-10
EP1282643A2 (de) 2003-02-12
WO2001083547A2 (en) 2001-11-08
EP1282643B1 (de) 2006-09-13
JP2003531918A (ja) 2003-10-28
EP1280820A2 (de) 2003-02-05
AU2001257631B2 (en) 2006-01-05
WO2001083547A3 (en) 2002-05-16
US20020156000A1 (en) 2002-10-24
JP2013056876A (ja) 2013-03-28
ES2231494T3 (es) 2005-05-16
US20120101028A1 (en) 2012-04-26
US8017726B2 (en) 2011-09-13
EP2314601A1 (de) 2011-04-27
DE60106423D1 (de) 2004-11-18
US6864355B1 (en) 2005-03-08
US6831065B2 (en) 2004-12-14
ATE339440T1 (de) 2006-10-15
DE60106423T2 (de) 2005-10-20
EP1280820B1 (de) 2004-10-13
WO2001083554A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
ATE339440T1 (de) Entzündungshemmende verbindungen und ihre verwendung
ATE277910T1 (de) Urazil verbindungen und deren verwendung
DE60222006D1 (de) Heterozyklische verbindungen und ihre verwendungen
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
EE200300071A (et) Kinasoliini derivaadid
DE60003874D1 (de) Resistmaterialien und Verbindungen
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
DE60027479D1 (de) Harzstruktur und ihre verwendung
DE60016326D1 (de) Wasser-absorbierende Zusammensetzung und ihre Verwendung
ATE298337T1 (de) Neue verwendung sowie neue n-azabicycloamid- verbindungen
ATE261449T1 (de) Thienopyrimidin verbindungen, ihre herstellung und verwendung
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
ATE398120T1 (de) Neue quinazolin-derivate
DE60230883D1 (de) Neue formulierungen und ihre verwendung
DE60027927D1 (de) Harzstruktur und ihre verwendung
DE60230608D1 (de) Tyra-gene und ihre verwendung
NO20021503D0 (no) Kinazolinoner
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DE60006970D1 (de) Fluorogene verbindungen und ihre verwendungen
DE50106596D1 (de) Haftklebemasse und ihre verwendung
NO20021502D0 (no) Kinazolinoner
DE69917777D1 (de) Benzazol-verbindungen und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties